Naloxone intranasal - Polyrizon
Latest Information Update: 05 Mar 2026
At a glance
- Originator Polyrizon
- Developer Polyrizon; The University of Parma
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Opioid-related disorders
Most Recent Events
- 27 Feb 2026 Pharmacodynamics data from a preclinical trials in Opioid related disorders were released by the Polyrizon
- 11 Dec 2025 Pharmacodynamics data from a preclinical trials in Opioid related disorders were released by the Polyrizon
- 03 Dec 2025 Pharmacodynamics data from a preclinical trials in Opioid related disorders were released by the Polyrizon